期刊文献+

Ki-67乳腺癌临床应用价值及其临界值界定的研究进展 被引量:16

Research progress on the clinical value of Ki-67 in breast cancer and its cut-off definition
原文传递
导出
摘要 Ki-67在临床上具有重要的应用价值,但其表达阳性率临界值的界定尚存有争议,给临床应用带来一定困难.本文总结了国内外在Ki-67对乳腺癌预后判断、临床指导治疗价值及其表 达阳性率临界值界定的研究,分析了各项研究存在差异的原因,并提出科学界定Ki-67表达阳性率临界值的必要性及临床重要性,从而为Ki-67在临床应用提供一定的理论依据. Ki-67 has an important application value in clinical practice.However,it is still a little tough in clinical application because of the debate on the cut-off definition of Ki-67 index.This review summarizes most studies on the prognostic and predictive value of Ki-67,analyzes the reasons for the discrepancies among the studies cited,and presents the necessity and clinical significance of scientifically defining the cut-off of Ki-67 index,providing a theoretical basis for Ki-67 in clinical application.
作者 陈青 吴克瑾
出处 《中华外科杂志》 CAS CSCD 北大核心 2015年第8期634-637,共4页 Chinese Journal of Surgery
关键词 乳腺肿瘤 KI-67抗原 Breast neoplasms Ki-67 antigen
  • 相关文献

参考文献31

  • 1GerdesJ, SchwabU, LemkeH, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J]. Int J Cancer, 1983, 31(1): 13-20. 被引量:1
  • 2GoldhirschA, IngleJN, GelberRD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20(8): 1319-1329. 被引量:1
  • 3FonatschC, DuchrowM, RiederH, et al. Assignment of the human Ki-67 gene (MK167) to 10q25-qter[J]. Genomics, 1991, 11(2): 476-477. 被引量:1
  • 4Harper-WynneC, RossG, SacksN, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention[J]. Cancer Epidemiol Biomarkers Prev, 2002, 11(7): 614-621. 被引量:1
  • 5ShokerBS, JarvisC, DaviesMP, et al. Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal,cancerous and precancerous breast lesions[J]. Br J Cancer, 2001, 84(8): 1064-1069. 被引量:1
  • 6BhatavdekarJM, PatelDD, ShahNG, et al. Prognostic significance of immunohistochemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis[J]. Ann Surg Oncol, 2000, 7(4): 305-311. 被引量:1
  • 7徐玲,刘荫华,叶京明,赵建新,段学宁,张澜波,张虹,王韫宏.乳腺癌组织Ki67表达与蒽环类联合紫杉类新辅助化疗效果的相关性[J].中华外科杂志,2010,48(6):450-453. 被引量:25
  • 8CserniG, V?r?sA, Liepniece-KareleI, et al. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values[J]. Breast, 2014, 23(3): 259-263. 被引量:1
  • 9de AzambujaE, CardosoF, de CastroG, et al. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients[J]. Br J Cancer, 2007, 96(10): 1504-1513. 被引量:1
  • 10Stuart-HarrisR, CaldasC, PinderSE, et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients[J]. Breast, 2008, 17(4): 323-334. 被引量:1

二级参考文献12

  • 1Therasse P, Arbuck SG, Eisenhaner EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92:205-216. 被引量:1
  • 2Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival. Breast, 2003, 12 : 320-327. 被引量:1
  • 3Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006, 24: 2019-2027. 被引量:1
  • 4Heller W, Mazhar D, Ward R, et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep, 2007, 17: 253-259. 被引量:1
  • 5Sehag CC, Heinrieh RL, Ganz PA. Karnofsky performance status revisited : reliability, validity, and guidelines. J Clin Oncol, 1984, 2 : 187-193. 被引量:1
  • 6Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16: 2672-2685. 被引量:1
  • 7Fisher ER, Wang J, Bryant J, et ah Pathobiology of preoperative chemotherapy : findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer, 2002, 95: 681- 695. 被引量:1
  • 8Schneeweiss A, Katretchko J, Sinn HP, et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs, 2004, 15: 127-135. 被引量:1
  • 9Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors : a study of preoperative treatment. Clin Cancer Res, 2004, 10: 6622-6628. 被引量:1
  • 10Wintzer HO, Zipfel I, Schuhe-Monting J, et al. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer, 1991, 67: 421-428. 被引量:1

共引文献24

同被引文献171

  • 1Yutong He,Di Liang,Daojuan Li,Baoen Shan,Rongshou Zheng,Siwei Zhang,Wenqiang Wei,Jie He.Incidence and mortality of laryngeal cancer in China, 2015[J].Chinese Journal of Cancer Research,2020,32(1):10-17. 被引量:29
  • 2陈铁,陈橼,吴金东,曹广鑫,李怀亮,侯炜晓,张一心,江晓晖.进展期胃癌组织中FOXP1和Ki67的表达及对患者预后的影响[J].南京医科大学学报(自然科学版),2020,40(8):1181-1185. 被引量:2
  • 3孙立春,隋广杰,于雁,庞慧,王艳颖,程慧.Skp2和p27蛋白在乳腺癌中表达及临床意义[J].肿瘤防治研究,2005,32(7):411-413. 被引量:5
  • 4RossJS, SlodkowskaEA, SymmansWF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine[J]. Oncologist, 2009, 14(4): 320-368. 被引量:1
  • 5BuzdarAU, IbrahimNK, FrancisD, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J]. J Clin Oncol, 2005, 23(16): 3676-3685. 被引量:1
  • 6GianniL, PienkowskiT, ImYH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32. 被引量:1
  • 7BuzdarAU, ValeroV, IbrahimNK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen[J]. Clin Cancer Res, 2007, 13(1):228-233. 被引量:1
  • 8GianniL, EiermannW, SemiglazovV, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384. 被引量:1
  • 9UntchM, FaschingPA, KonecnyGE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups[J]. J Clin Oncol, 2011, 29(25): 3351-3357. 被引量:1
  • 10BaselgaJ, BradburyI, EidtmannH, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multi-centre, phase 3 trial[J]. Lancet, 2012, 379(9816): 633-640. 被引量:1

引证文献16

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部